Skip to main content
. 2023 Sep 22;101(11):1449–1464. doi: 10.1007/s00109-023-02369-6

Fig. 1.

Fig. 1

LOXL2 is highly expressed in patients with gemcitabine-resistant pancreatic cancer and gemcitabine-resistant pancreatic cancer cells. A Immunohistochemical staining of LOXL2 in pancreatic cancer tissues. B Bar graphs for LOXL2 levels in tissues between the resistant and sensitive groups. C Dot plot of LOXL2 gene expression level in purified mRNA from pancreatic cancer patient tissue. D Schematic showing the establishment of a gemcitabine-resistant cell line. E WST-1 assay of parental Miapaca2 (Mia Con) and gemcitabine-resistant (Mia GR) cells exposed to gemcitabine at different concentrations for 72 h. F and G Relative mRNA levels of the indicated genes in Miapaca2 and Mia GR cells. H The protein expression of LOXL2, RRM1, hENT1, and DCK was compared between Mia Con and Mia GR cells using western blot analysis. All western blot experiments were performed at least three times